OTC : SGIOF

Shionogi & Co., Ltd.

$17.55 USD

$0 (0.0%)

Volume
500
Average Volume
733
Market Capitalization
$14.93B
P/E Ratio
11.93
Dividend Yield
2.47%
Price Target
Year High
$26.00
Year Low
$14.25
Day High
—
Day Low
—
Payout Ratio
$0.27
Current Ratio
$1.58
Company Overview

OTC

Isao Teshirogi

Drug Manufacturers - Specialty & Generic

Healthcare

SGIOF

6223

JP

USD

https://www.shionogi.com

81 6 6202 2161

N/A

0001281721

Liquidity Metrics

0.41

1.58

1.46

0.86

0.27

Sales & Valuation

$502.82B

4.90

1.45

12.29

233.97

Profitability

$242.87

$206.45B

41.06%

47.81%

13.65%

7.96%

P/E Metrics

11.93

0.59

0.59

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Poll Results

About Shionogi & Co., Ltd. (OTC:SGIOF) Stock

Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral medication targeting influenza; and Tivicay, which is used in HIV management. Shionogi actively pursues the development of numerous compounds addressing a wide array of medical conditions. Its investigational pipeline features treatments for opioid-induced constipation (Symproic); inflammatory pain (S-120083); neuropathic pain (S-010887, sivopixant, and S-637880 for low back pain); insomnia (S-117957); and central nervous sys ... tem disorders such as sleep apnea syndrome, refractory/unexplained chronic cough (both sivopixant), depression (Zuranolone), and attention-deficit/hyperactivity disorder (SDT-001). The company also has candidates for Fragile X syndrome and Alzheimer's disease (BPN14770), as well as obesity (S-237648, S-309309). Its robust research pipeline further extends to treatments for conditions including decompensated liver cirrhosis (ADR-001) and NASH (S-723595). In oncology, Shionogi is advancing S-588410 for esophageal and bladder cancers, S-488210 for head and neck squamous cell carcinoma, and S-588210, S-222611, and S-531011 for various solid tumors and malignancies. Other investigational therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. The company is also heavily invested in COVID-19 therapeutics, with S-600918, S-217622, and S-555739 aimed at treating the virus and managing its worsening effects. Additionally, Shionogi provides diagnostic antibody test kits specifically for COVID-19. Shionogi & Co., Ltd. collaborates with academic and research institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University on joint initiatives, particularly in the development of antimalarial medications. Founded in Osaka, Japan, in 1878, the organization initially operated under the name Shionogi Shoten Co., Ltd. before adopting its current corporate identity, Shionogi & Co., Ltd., in 1943.

New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure

2026-05-13 17:08:00

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare.

Frequently Asked Questions

What is the current Shionogi & Co., Ltd. (SGIOF) stock price?

Shionogi & Co., Ltd.(OTC:SGIOF) stock price is $17.55 in the last trading session. During the trading session, SGIOF stock reached the peak price of $26 while $14.25 was the lowest point it dropped to. The percentage change in SGIOF stock occurred in the recent session was 0.0% while the dollar amount for the price change in SGIOF stock was $0.

SGIOF's industry and sector of operation?

The OTC listed SGIOF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of SGIOF?

Takuji Fujiwara | Accounting & Finance Manager
Kazuhiro Hatanaka | Senior Executive Officer & Senior Vice President of Corporate Supervisory Unit
Takeshi Shiota | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div.
Toshinobu Iwasaki | Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit
Yoshimasa Kyokawa | Vice President of Corporate Communications & Secretary Office

How many employees does SGIOF have?

Number of SGIOF employees currently stands at 6223. SGIOF operates from 1-8, Doshomachi 3-chome, Osaka, OS 541-0045, JP.

Link for SGIOF official website?

Official Website of SGIOF is: https://www.shionogi.com

How do I contact SGIOF?

SGIOF could be contacted at phone #81 6 6202 2161 and can also be accessed through its website. SGIOF operates from 1-8, Doshomachi 3-chome, Osaka, OS 541-0045, JP.

How many shares of SGIOF are traded daily?

The average number of SGIOF shares traded daily for last 3 months was 733.

What is the market cap of SGIOF currently?

The market value of SGIOF currently stands at $14.93B with its latest stock price at $17.55